FDA pre-emption case at the US Supreme Court

17 December 2007

The US Supreme Court has heard oral arguments in Riegel versus Medtronic, a dispute over whether the express pre-emption provision of the 1976 Food and Drug Cosmetic Act overrides state legislation that allows people to claim damages for injuries caused by drugs and medical devices. The case involves USA-based medical device manufacturer Medtronic, but involves the same legislation as for drug safety claims. Drugmakers argue that compliance with the Food and Drug Administration's safety requirements should not be "second-guessed" by juries and state judges.

According to Rob Clark, a spokesman for the firm, drug companies are in a "Catch-22 between complying with FDA regulations on the one hand and still being subject to state liability on the other." Trial lawyers, who can collect up to one third of damage awards, and consumer groups argue that the federal agency is not capable of ensuring that the data on which safety decisions are made is accurate. There are also concerns about the FDA's resources for policing drug safety. A recent study by the FDA's Science Board "found that the agency was so poorly organized and short of funds that it could not adequately protect the public from dangerous drugs," the Los Angeles Times reported.

Opposing this viewpoint, Karen Barth Menzies, a lawyer, told the LA Times that a ruling in favor of Medtronic would "take away the last possible safety net against unfettered corporate misbehavior and negligence."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight